Plasma and cerebrospinal fluid cholesterol esterification is hampered in Alzheimer’s disease

[1]  K. Ikewaki,et al.  HDL Functions—Current Status and Future Perspectives , 2023, Biomolecules.

[2]  J. Trojanowski,et al.  ApoJ/Clusterin concentrations are determinants of cerebrospinal fluid cholesterol efflux capacity and reduced levels are associated with Alzheimer’s disease , 2022, Alzheimer's Research & Therapy.

[3]  K. Blennow,et al.  Apolipoprotein E imbalance in the cerebrospinal fluid of Alzheimer’s disease patients , 2022, Alzheimer's Research & Therapy.

[4]  D. Giuliani,et al.  PCSK9 Affects Astrocyte Cholesterol Metabolism and Reduces Neuron Cholesterol Supplying In Vitro: Potential Implications in Alzheimer’s Disease , 2022, International journal of molecular sciences.

[5]  D. Galimberti,et al.  A Novel Automated Chemiluminescence Method for Detecting Cerebrospinal Fluid Amyloid-Beta 1-42 and 1-40, Total Tau and Phosphorylated-Tau: Implications for Improving Diagnostic Performance in Alzheimer’s Disease , 2022, Biomedicines.

[6]  M. Adorni,et al.  Effects of PCSK9 inhibitors on HDL cholesterol efflux and serum cholesterol loading capacity in familial hypercholesterolemia subjects: a multi-lipid-center real-world evaluation , 2022, Frontiers in molecular biosciences.

[7]  Jade I Hawksworth,et al.  A new generation of AD biomarkers: 2019 to 2021 , 2022, Ageing Research Reviews.

[8]  F. Veglia,et al.  Plasma FA composition in familial LCAT deficiency indicates SOAT2-derived cholesteryl ester formation in humans , 2022, Journal of lipid research.

[9]  G. Ricevuti,et al.  Blood-Based Biomarkers for Alzheimer’s Disease Diagnosis and Progression: An Overview , 2022, Cells.

[10]  M. Adorni,et al.  Emerging role of HDL in brain cholesterol metabolism and neurodegenerative disorders. , 2022, Biochimica et biophysica acta. Molecular and cell biology of lipids.

[11]  C. Cervellati,et al.  Association between Serum Concentrations of Apolipoprotein A-I (ApoA-I) and Alzheimer’s Disease: Systematic Review and Meta-Analysis , 2021, Diagnostics.

[12]  M. Adorni,et al.  High Density Lipoprotein Cholesterol Efflux Capacity and Atherosclerosis in Cardiovascular Disease: Pathophysiological Aspects and Pharmacological Perspectives , 2021, Cells.

[13]  B. Laurent,et al.  APOE and Alzheimer’s Disease: From Lipid Transport to Physiopathology and Therapeutics , 2021, Frontiers in Neuroscience.

[14]  A. Sodero.  24S‐hydroxycholesterol: Cellular effects and variations in brain diseases , 2020, Journal of neurochemistry.

[15]  L. Calabresi,et al.  Genetic, biochemical, and clinical features of LCAT deficiency: update for 2020. , 2020, Current opinion in lipidology.

[16]  K. Blennow,et al.  Quantification of total apolipoprotein E and its isoforms in cerebrospinal fluid from patients with neurodegenerative diseases , 2020, Alzheimer's Research & Therapy.

[17]  Bihong Zhu,et al.  Association of Clusterin Levels in Cerebrospinal Fluid with Synaptic Degeneration Across the Alzheimer’s Disease Continuum , 2020, Neuropsychiatric disease and treatment.

[18]  D. Galimberti,et al.  ABCA1- and ABCG1-mediated cholesterol efflux capacity of cerebrospinal fluid is impaired in Alzheimer’s disease[S] , 2019, Journal of Lipid Research.

[19]  Gianvito Grasso,et al.  The Extent of Human Apolipoprotein A-I Lipidation Strongly Affects the β-Amyloid Efflux Across the Blood-Brain Barrier in vitro , 2019, Front. Neurosci..

[20]  J. Montaner,et al.  Characterization of ApoJ-reconstituted high-density lipoprotein (rHDL) nanodisc for the potential treatment of cerebral β-amyloidosis , 2017, Scientific Reports.

[21]  K. Blennow,et al.  Reduced Cerebrospinal Fluid Concentration of Apolipoprotein A-I in Patients with Alzheimer's Disease. , 2017, Journal of Alzheimer's disease : JAD.

[22]  Keith A. Johnson,et al.  A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers , 2016, Neurology.

[23]  H. Chui,et al.  ABCA1‐Mediated Cholesterol Efflux Capacity to Cerebrospinal Fluid Is Reduced in Patients With Mild Cognitive Impairment and Alzheimer's Disease , 2016, Journal of the American Heart Association.

[24]  L. Tremolizzo,et al.  Beta-Amyloid Plasma Levels in Adolescents with Anorexia Nervosa of the Restrictive Type , 2015, Neuropsychobiology.

[25]  M. Phillips.  Apolipoprotein E isoforms and lipoprotein metabolism , 2014, IUBMB life.

[26]  C. Wellington,et al.  HDL and cholesterol handling in the brain. , 2014, Cardiovascular research.

[27]  D. Rader,et al.  Molecular Mechanisms Responsible for the Differential Effects of ApoE3 and ApoE4 on Plasma Lipoprotein–Cholesterol Levels , 2013, Arteriosclerosis, thrombosis, and vascular biology.

[28]  Markus R Wenk,et al.  Comparative Lipidomic Analysis of Mouse and Human Brain with Alzheimer Disease* , 2011, The Journal of Biological Chemistry.

[29]  A. Passaro,et al.  Plasma 24S-hydroxycholesterol levels in elderly subjects with late onset Alzheimer's disease or vascular dementia: a case-control study , 2011, BMC neurology.

[30]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[31]  H. Saito,et al.  Molecular basis for the differences in lipid and lipoprotein binding properties of human apolipoproteins E3 and E4. , 2010, Biochemistry.

[32]  I. Björkhem,et al.  Genetic connections between neurological disorders and cholesterol metabolism , 2010, Journal of Lipid Research.

[33]  H. Hayashi,et al.  Formation and function of apolipoprotein E-containing lipoproteins in the nervous system. , 2010, Biochimica et biophysica acta.

[34]  K. Weisgraber,et al.  Amino-terminal domain stability mediates apolipoprotein E aggregation into neurotoxic fibrils. , 2006, Journal of molecular biology.

[35]  P. Barter,et al.  Regulation of reconstituted high density lipoprotein structure and remodeling by apolipoprotein E Published, JLR Papers in Press, February 1, 2006. , 2006, Journal of Lipid Research.

[36]  F. Zimetti,et al.  Measurement of cholesterol bidirectional flux between cells and lipoproteins Published, JLR Papers in Press, December 3, 2005. , 2006, Journal of Lipid Research.

[37]  I. Gelissen,et al.  ABCA1 and ABCG1 Synergize to Mediate Cholesterol Export to ApoA-I , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[38]  E. Favari,et al.  Impaired ATP‐binding cassette transporter A1‐mediated sterol efflux from oxidized LDL‐loaded macrophages , 2005, FEBS letters.

[39]  E. Schaefer,et al.  Differential effects of HDL subpopulations on cellular ABCA1- and SR-BI-mediated cholesterol efflux Published, JLR Papers in Press, August 1, 2005. DOI 10.1194/jlr.M500187-JLR200 , 2005, Journal of Lipid Research.

[40]  G. Franceschini,et al.  The Molecular Basis of Lecithin:Cholesterol Acyltransferase Deficiency Syndromes: A Comprehensive Study of Molecular and Biochemical Findings in 13 Unrelated Italian Families , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[41]  Peter Schönknecht,et al.  Cerebrospinal fluid 24S-hydroxycholesterol is increased in patients with Alzheimer's disease compared to healthy controls , 2002, Neuroscience Letters.

[42]  A. Jonas.  Lecithin cholesterol acyltransferase. , 2000, Biochimica et biophysica acta.

[43]  Giovanni B. Frisoni,et al.  Gene dose of the ε4 allele of apolipoprotein E and disease progression in sporadic late‐onset alzheimer's disease , 1995 .

[44]  G. Frisoni,et al.  Apolipoprotein E epsilon 4 allele frequency in vascular dementia and Alzheimer's disease. , 1994, Stroke.

[45]  L. Calabresi,et al.  Structure of HDL: particle subclasses and molecular components. , 2015, Handbook of experimental pharmacology.

[46]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[47]  G. Frisoni,et al.  Gene dose of the epsilon 4 allele of apolipoprotein E and disease progression in sporadic late-onset Alzheimer's disease. , 1995, Annals of neurology.

[48]  G. Frisoni,et al.  Apolipoprotein E epsilon 4 allele in Alzheimer's disease and vascular dementia. , 1994, Dementia.